Ohtomo Yoshiyuki, Umino Daisuke, Takada Masaru, Niijima Shinichi, Fujinaga Shuichiro, Shimizu Toshiaki
Department of Pediatrics, Juntendo University Nerima Hospital, Tokyo, Japan.
Pediatr Int. 2013 Dec;55(6):737-40. doi: 10.1111/ped.12158. Epub 2013 Aug 21.
The major pathogenic factors involved in nocturnal enuresis are nocturnal polyuria, small bladder capacity and/or detrusor overactivity, and a high arousal threshold. Desmopressin is the first-line therapy for the patients with diuresis-dependent nocturnal enuresis. Yokukansan, a traditional Japanese medicine, has been used in Japan to treat patients with nervousness, insomnia, and children with night terrors and temper tantrums. We experienced the positive effect of Yokukansan in some of the patients who did not respond well to desmopressin therapy.
In total, 32 children with monosymptomatic nocturnal enuresis with nocturnal polyuria were treated with oral desmopressin melt tablets, which were approved for clinical use in Japan on 29 May 2012. This treatment was effective for 14 of them. For the rest (n = 18), Yokukansan was introduced in combination with desmopressin.
Yokukansan was effective for 12 out of the 18 cases.
Yokukansan should be a candidate for the medication of nocturnal enuresis.
夜间遗尿的主要致病因素包括夜间多尿、膀胱容量小和/或逼尿肌过度活动，以及觉醒阈值高。去氨加压素是治疗依赖利尿的夜间遗尿患者的一线疗法。日本传统药物抑肝散在日本已被用于治疗焦虑、失眠患者以及患有夜惊和发脾气的儿童。我们在一些对去氨加压素治疗反应不佳的患者中体验到了抑肝散的积极效果。
总共32例患有夜间多尿的单症状性夜间遗尿儿童接受了口服去氨加压素溶片治疗，该药物于2012年5月29日在日本获批用于临床。其中14例治疗有效。对于其余18例，加用抑肝散与去氨加压素联合治疗。
18例中有12例使用抑肝散有效。
抑肝散应成为夜间遗尿药物治疗的候选药物。
